Drugs for COVID-19

The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live fecal microbiota spores, for prevention of additional recurrences of Clostridioides difficile infection (CDI) in adults. Vowst is the first orally administered microbiota-based treatment to be approved for this indication. A rectally-administered live fecal microbiota-based suspension (Rebyota) was approved in 2022 for the same indication.1 Neither product is approved for acute treatment of CDI.

INITIAL EPISODES OF CDI — All...  Continue reading

Previous Issue: 1676
May 15, 2023
Coming Soon
Drugs for Migraine
Ibrexafungerp (Brexafemme) for Recurrent Vulvovaginal Candidiasis
Inspire for Obstructive Sleep Apnea
OTC Ivermectin (Sklice) for Head Lice